Adagio Medical Holdings, Inc Common Stock (ADGM)vsJohnson & Johnson (JNJ)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.06
+6.39%
HEALTHCARE · Cap: $2.28M
JNJ
Johnson & Johnson
$276.22
+1.43%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 72507196% more annual revenue ($99.33B vs $137,000). JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
ADGM
Avoid33
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Debt/Equity. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 33/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?